- Motley Fool•35 minutes ago
How Biogen and Gilead Sciences stack up in a battle of big biotech stocks.
- American City Business Journals•7 hours ago
A new biotech has launched in Waltham with a management team made up of former Biogen executives and $38 million in financing from Pfizer, former Genzyme CEO Henri Termeer and other prominent investors. Arrakis Therapeutics said it will focus on developing potential treatments for neurology, cancer and rare genetic disorders that target RNA, the all-important molecules that translate the instructions in DNA into proteins in the body. The $38 million Series A financing was led by California venture capital firm Canaan Partners.
- Motley Fool•4 days ago
The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||288.34 x 200|
|Ask||288.41 x 100|
|Day's Range||284.27 - 288.80|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|